Targeting GPX4 palmitoylation to boost antitumor immunity.

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2025-05-14 DOI:10.1016/j.trecan.2025.05.001

Daehee Hwang, Whitney S Henry

引用次数: 0

Abstract

Despite significant milestones in cancer immunotherapy, tumor cells often escape immune surveillance. Zhou et al. revealed that the pivotal ferroptosis suppressor glutathione peroxidase 4 (GPX4) can undergo palmitoylation by zDHHC8, enhancing ferroptosis resistance. This study highlights the potential of targeting GPX4 palmitoylation to enhance cytotoxic T cell-mediated ferroptosis of tumor cells.

查看原文本刊更多论文

靶向GPX4棕榈酰化增强抗肿瘤免疫。

尽管癌症免疫治疗取得了重大进展，但肿瘤细胞经常逃避免疫监视。Zhou等人发现关键的铁下垂抑制因子谷胱甘肽过氧化物酶4 （GPX4）可被zDHHC8棕榈酰化，增强铁下垂抗性。本研究强调了靶向GPX4棕榈酰化以增强细胞毒性T细胞介导的肿瘤细胞铁下垂的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.